Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Cardioprotective effects of ω -3 PUFAs in chronic kidney disease.

Lee SM, An WS.

Biomed Res Int. 2013;2013:712949. doi: 10.1155/2013/712949. Epub 2013 Apr 4. Review.

2.

Cardioprotective mechanism of omega-3 polyunsaturated fatty acids.

Endo J, Arita M.

J Cardiol. 2016 Jan;67(1):22-7. doi: 10.1016/j.jjcc.2015.08.002. Epub 2015 Sep 8. Review.

3.

The role of omega-3 polyunsaturated fatty acids in cardiovascular health.

Barrett SJ.

Altern Ther Health Med. 2013;19 Suppl 1:26-30. Review.

PMID:
23981464
4.

Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis.

Smesny S, Milleit B, Hipler UC, Milleit C, Schäfer MR, Klier CM, Holub M, Holzer I, Berger GE, Otto M, Nenadic I, Berk M, McGorry PD, Sauer H, Amminger GP.

Mol Psychiatry. 2014 Mar;19(3):317-24. doi: 10.1038/mp.2013.7. Epub 2013 Mar 12.

PMID:
23478748
5.

Differential dose effect of fish oil on inflammation and adipose tissue gene expression in chronic kidney disease patients.

Guebre-Egziabher F, Debard C, Drai J, Denis L, Pesenti S, Bienvenu J, Vidal H, Laville M, Fouque D.

Nutrition. 2013 May;29(5):730-6. doi: 10.1016/j.nut.2012.10.011. Epub 2013 Jan 30.

PMID:
23375525
6.

Altered erythrocyte membrane fatty acid profile in typical Rett syndrome: effects of omega-3 polyunsaturated fatty acid supplementation.

Signorini C, De Felice C, Leoncini S, Durand T, Galano JM, Cortelazzo A, Zollo G, Guerranti R, Gonnelli S, Caffarelli C, Rossi M, Pecorelli A, Valacchi G, Ciccoli L, Hayek J.

Prostaglandins Leukot Essent Fatty Acids. 2014 Nov;91(5):183-93. doi: 10.1016/j.plefa.2014.08.002. Epub 2014 Sep 6.

PMID:
25240461
7.

Plasma and erythrocyte membrane phospholipids and fatty acids in Italian general population and hemodialysis patients.

Dessì M, Noce A, Bertucci P, Noce G, Rizza S, De Stefano A, Manca di Villahermosa S, Bernardini S, De Lorenzo A, Di Daniele N.

Lipids Health Dis. 2014 Mar 21;13:54. doi: 10.1186/1476-511X-13-54.

8.

Effects of omega-3 polyunsaturated fatty acids on cardiac myocyte protection.

Bei R, Frigiola A, Masuelli L, Marzocchella L, Tresoldi I, Modesti A, Galvano F.

Front Biosci (Landmark Ed). 2011 Jan 1;16:1833-43. Review.

PMID:
21196268
9.

Dietary fat modification in patients with chronic kidney disease: n-3 fatty acids and beyond.

Huang X, Lindholm B, Stenvinkel P, Carrero JJ.

J Nephrol. 2013 Nov-Dec;26(6):960-74. doi: 10.5301/jn.5000284. Epub 2013 Oct 3. Review.

PMID:
24249210
10.

Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients.

Rasic-Milutinovic Z, Perunicic G, Pljesa S, Gluvic Z, Sobajic S, Djuric I, Ristic D.

Ren Fail. 2007;29(3):321-9.

PMID:
17497447
11.

Omega-3 fatty acid supplementation increases 1,25-dihydroxyvitamin D and fetuin-A levels in dialysis patients.

An WS, Lee SM, Son YK, Kim SE, Kim KH, Han JY, Bae HR, Rha SH, Park Y.

Nutr Res. 2012 Jul;32(7):495-502. doi: 10.1016/j.nutres.2012.06.005. Epub 2012 Jul 20.

PMID:
22901557
12.
13.

[Molecular mechanisms of action and health benefits of polyunsaturated fatty acids].

Rodríguez-Cruz M, Tovar AR, del Prado M, Torres N.

Rev Invest Clin. 2005 May-Jun;57(3):457-72. Review. Spanish.

PMID:
16187707
14.

Cardiovascular protective effects of n-3 polyunsaturated fatty acids with special emphasis on docosahexaenoic acid.

Hirafuji M, Machida T, Hamaue N, Minami M.

J Pharmacol Sci. 2003 Aug;92(4):308-16. Review.

15.

Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes.

Hartweg J, Farmer AJ, Holman RR, Neil A.

Curr Opin Lipidol. 2009 Feb;20(1):30-8.

PMID:
19133409
16.

The effects of omega-3 polyunsaturated fatty acids on cardiac rhythm: a critical reassessment.

Billman GE.

Pharmacol Ther. 2013 Oct;140(1):53-80. doi: 10.1016/j.pharmthera.2013.05.011. Epub 2013 Jun 2. Review.

PMID:
23735203
17.

Omega-3 fatty acids and HDL. How do they work in the prevention of cardiovascular disease?

Burillo E, Martín-Fuentes P, Mateo-Gallego R, Baila-Rueda L, Cenarro A, Ros E, Civeira F.

Curr Vasc Pharmacol. 2012 Jul;10(4):432-41. Review.

PMID:
22339302
18.

The effects of omega-3 fatty acid on vitamin D activation in hemodialysis patients: a pilot study.

Lee SM, Son YK, Kim SE, An WS.

Mar Drugs. 2015 Jan 28;13(2):741-55. doi: 10.3390/md13020741.

19.

Omega-3 Fatty Acids and Primary and Secondary Prevention of Cardiovascular Disease.

Cao Y, Lu L, Liang J, Liu M, Li X, Sun R, Zheng Y, Zhang P.

Cell Biochem Biophys. 2015 May;72(1):77-81. doi: 10.1007/s12013-014-0407-5. Review.

PMID:
25427890
20.

Cardiovascular disease and its relationship with chronic kidney disease.

Liu M, Li XC, Lu L, Cao Y, Sun RR, Chen S, Zhang PY.

Eur Rev Med Pharmacol Sci. 2014 Oct;18(19):2918-26. Review.

Supplemental Content

Support Center